Imugene (ASX:IMU) said efficacy data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with relapsed/refractory diffuse large B-cell lymphoma showed a best overall response rate of 79%, with 11 out of 14 patients showing a response to treatment, according to a Monday Australian bourse filing.

Two new patients became evaluable for responses, and both achieved a partial response, the filing said. The patients are being treated with azer-cel and interleukin 2.

The company is enrolling patients to the phase 1b azer-cel trial at 10 US sites, with up to six sites in Australia planned.

Imugene's shares jumped 10% in recent trading on Monday.